Literature DB >> 32648321

Characterization of metabolic activity, isozyme contribution and species differences of bavachin, and identification of efflux transporters for bavachin-O-glucuronide in HeLa1A1 cells.

Yang Li1, Chunxia Xu1, Jinjin Xu1, Zifei Qin2,3, Shishi Li1, Liufang Hu1, Zhihong Yao1,2, Frank J Gonzalez4, Xinsheng Yao1,2.   

Abstract

OBJECTIVES: Bavachin is a bioactive natural flavonoid with oestrogen-like activity. Here, we aimed to investigate its metabolic and disposal fates involving in CYPs, UGTs and efflux transporters.
METHODS: Phase I metabolism and glucuronidation were performed by human liver microsomes (HLM). Reaction phenotyping and activity correlation analysis were performed to identify the main CYP and UGT isozymes. Chemical inhibition and gene knock-down approaches were employed to explore the function of BCRP and MRPs. KEY
FINDINGS: Five phase I metabolites (M1-M5) and three glucuronides (G1-G3) were identified. The CLint values for M4 and G1 by HLM were 127.99 and 1159.07 μl/min per mg, respectively. Reaction phenotyping results suggested CYP1A1 (208.85 μl/min per mg) and CYP2C9 (107.51 μl/min per mg), and UGT1A1 (697.19 μl/min per mg), UGT1A7 (535.78 μl/min per mg), UGT1A8 (247.72 μl/min per mg) and UGT1A9 (783.68 μl/min per mg) all participated in the metabolism of bavachin. In addition, activity correlation analysis also supported the results above. Furthermore, the metabolism exhibited marked species differences, and rabbits were the appropriate model animals. Moreover, MRP4 was identified as the main contributor based on chemical inhibition and gene silencing approaches.
CONCLUSIONS: CYP1A1 and CYP2C9, UGT1A1, UGT1A7, UGT1A8 and UGT1A9, and MRP4 all played important roles in the metabolism and disposition of bavachin.
© 2020 Royal Pharmaceutical Society.

Entities:  

Keywords:  CYPs, UGTs; HeLa1A1 cells; MRPs; bavachin; metabolism

Mesh:

Substances:

Year:  2020        PMID: 32648321      PMCID: PMC8865092          DOI: 10.1111/jphp.13324

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   4.810


  41 in total

1.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

2.  Pharmacokinetic interplay of phase II metabolism and transport: a theoretical study.

Authors:  Baojian Wu
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

3.  The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells.

Authors:  Shishi Li; Jinjin Xu; Zhihong Yao; Liufang Hu; Zifei Qin; Hao Gao; Kristopher W Krausz; Frank J Gonzalez; Xinsheng Yao
Journal:  Chem Biol Interact       Date:  2018-09-17       Impact factor: 5.192

4.  Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

Authors:  K Ikeda; K Yoshisue; E Matsushima; S Nagayama; K Kobayashi; C A Tyson; K Chiba; Y Kawaguchi
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 5.  Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.

Authors:  Janne T Backman; Anne M Filppula; Mikko Niemi; Pertti J Neuvonen
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

6.  Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines.

Authors:  Akiko Nakamura; Miki Nakajima; Hiroyuki Yamanaka; Ryoichi Fujiwara; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2008-05-14       Impact factor: 3.922

7.  Wuzhi tablet (Schisandra Sphenanthera extract) protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of NRF2-ARE and p53/p21 pathways.

Authors:  Xiaomei Fan; Yiming Jiang; Ying Wang; Huasen Tan; Hang Zeng; Yongtao Wang; Pan Chen; Aijuan Qu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Drug Metab Dispos       Date:  2014-09-12       Impact factor: 3.922

8.  Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells.

Authors:  Hua Sun; Xiao Wang; Xiaotong Zhou; Danyi Lu; Zhiguo Ma; Baojian Wu
Journal:  Drug Metab Dispos       Date:  2015-08-03       Impact factor: 3.922

9.  Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus.

Authors:  Xiao-Ling Qin; Tao Yu; Ling-Jue Li; Ying Wang; Hao-Min Gu; Yong-Tao Wang; Min Huang; Hui-Chang Bi
Journal:  Phytomedicine       Date:  2012-12-23       Impact factor: 5.340

10.  Identification and characterization of naturally occurring inhibitors against UDP-glucuronosyltransferase 1A1 in Fructus Psoraleae (Bu-gu-zhi).

Authors:  Xin-Xin Wang; Xia Lv; Shi-Yang Li; Jie Hou; Jing Ning; Jia-Yue Wang; Yun-Feng Cao; Guang-Bo Ge; Bin Guo; Ling Yang
Journal:  Toxicol Appl Pharmacol       Date:  2015-09-05       Impact factor: 4.460

View more
  4 in total

1.  Potential metabolism determinants and drug-drug interactions of a natural flavanone bavachinin.

Authors:  Xinqiang Li; Han Xing; Zifei Qin; Jing Yang; Peile Wang; Xiaojian Zhang; Zhihong Yao; Xinsheng Yao
Journal:  RSC Adv       Date:  2020-09-23       Impact factor: 4.036

2.  Pharmacokinetic study on the interaction between pachymic acid and bavachin and its potential mechanism.

Authors:  Jie Zhang; Lu Liu; Hong Li; Bin Zhang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

3.  Identification of naturally occurring inhibitors in Xian-Ling-Gu-Bao capsule against the glucuronidation of estrogens.

Authors:  Liangliang He; Chunxia Xu; Ziying Wang; Shuyi Duan; Jinjin Xu; Chuan Li; Xinsheng Yao; Frank J Gonzalez; Zifei Qin; Zhihong Yao
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

4.  Investigation on the metabolic characteristics of isobavachin in Psoralea corylifolia L. (Bu-gu-zhi) and its potential inhibition against human cytochrome P450s and UDP-glucuronosyltransferases.

Authors:  Han Xing; Jing Yang; Kaidi Ren; Zifei Qin; Peile Wang; Xiaojian Zhang; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Pharmacol       Date:  2020-08-04       Impact factor: 4.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.